Home » Posts tagged 'postmenopausal osteoporosis'
Tag Archives: postmenopausal osteoporosis
Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
WALTHAM, Mass., Dec. 21, 2014 (GLOBE NEWSWIRE) — Radius Health, Inc. today announced positive top-line 18-month fracture results from the Company’s Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.
BA058; BIM-44058; CAS 247062-33-5
MW 3960.5896, MF C174 H300 N56 O49
NAME………C2.29-methyl(22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),31-L-leucine(I>L))human parathyroid hormone-related protein-(1-34)-proteinamide
BIM-44058 is a 34 amino acid analog of native human PTHrP currently in phase III clinical trials at Radius Health for the treatment of postmenopausal osteoporosis. Radius is also developing a microneedle transdermal patch using a 3M drug delivery system in phase II clinical trials. The drug candidate was originally developed at Biomeasure (a subsidiary of Ipsen), and was subsequently licensed to Radius and Teijin Pharma.
A peptide of the formula:[Glu22, 25, Leu23, 28, 31, Lys26, Aib29, Nle30]hPTHrP(1-34)NH2;[Glu22, 25, Leu23, 28, 30, 31, Lys26, Aib29]hPTHrP(1-34)NH2; [Glu22, 25,29, Leu23, 28, 30, 31, Lys26]hpTHrP(1-34)NH2; [Glu22, 25, 29, Leu23, 28, 31, Lys26, Nle30]hPTHrP(1-34)NH2; [Ser1, Ile5, Met8, Asn10, Leu11, 23, 28, 31, His14, Cha15, Glu22, 25, Lys26, 30, Aib29]hPTHrP (1-34)NH2; [Cha22, Leu23, 28, 31, Glu25, 29, Lys26, Nle30]hPTHrP(1-34)NH2; [Cha7, 11, 15]hPTHrP(1-34)NH2; [Cha7, 8, 15]hPTHrP(1-34)NH2; [Glu22, Leu23, 28, Aib25, 29, Lys26]hpTHrP(1-34)NH2; [Aib29]hPTHrP(1-34)NH2; [Glu22, 25, Leu23, 28, 31, Lys26, Aib29, 30]hPTHrP(1-34)NH2; [Glu22, 25, Leu23, 28, 31, Lys26, Aib29]hPTHrP(1-34)NH2; [Glu22, 25, Leu23, 28, 31, Aib26, 29, Lys30] hPTHrP(1-34)NH2; or [Leu27, Aib29]hPTH(1-34)NH2; or a pharmaceutically acceptable salt thereof.
|EP5026436A||Title not available|
|US3773919||Oct 8, 1970||Nov 20, 1973||Du Pont||Polylactide-drug mixtures|
|US4767628||Jun 29, 1987||Aug 30, 1988||Imperial Chemical Industries Plc||Polylactone and acid stable polypeptide|
|WO1994001460A1 *||Jul 13, 1993||Jan 20, 1994||Syntex Inc||Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis|
|WO1994015587A2||Jan 5, 1994||Jul 21, 1994||Steven A Jackson||Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides|
|WO1997002834A1 *||Jul 3, 1996||Jan 30, 1997||Biomeasure Inc||Analogs of parathyroid hormone|
|WO1997002834A1 *||3 Jul 1996||30 Jan 1997||Biomeasure Inc||Analogs of parathyroid hormone|
|WO2008063279A2 *||3 Oct 2007||29 May 2008||Radius Health Inc||A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof|
|US5695955 *||23 May 1995||9 Dec 1997||Syntex (U.S.A.) Inc.||Gene expressing a nucleotide sequence encoding a polypeptide for treating bone disorder|
|US20030166836 *||6 Nov 2002||4 Sep 2003||Societe De Conseils De Recherches Et D’application Scientefiques, S.A.S., A France Corporation||Analogs of parathyroid hormone|
|US20050282749 *||14 Jan 2005||22 Dec 2005||Henriksen Dennis B||Glucagon-like peptide-1 (GLP-1); immunotherapy; for treatment of obesity|